Adjusting prednisone using blood eosinophils reduces exacerbations and improves asthma control in difficult patients with asthma

Respirology

Volumn 20, Issue 8, 2015, Pages 1282-1284

  Wark, Peter A B ^a   McDonald, Vanessa M ^a   Gibson, Peter G ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

asthma; clinical allergy and immunology; clinical respiratory medicine; eosinophil; inflammation

Indexed keywords

BECLOMETASONE; CORTICOSTEROID; ITRACONAZOLE; MONTELUKAST; MUSCARINIC AGENT; OMALIZUMAB; PREDNISONE; THEOPHYLLINE; ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE CALCULATION; DRUG EFFICACY; EOSINOPHIL COUNT; EOSINOPHILIA; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SYMPTOM; TREATMENT DURATION; AGED; ALGORITHM; BLOOD; DISEASE COURSE; EOSINOPHIL; LEUKOCYTE COUNT; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-INFLAMMATORY AGENTS; ASTHMA; DISEASE PROGRESSION; EOSINOPHILS; HUMANS; LEUKOCYTE COUNT; MIDDLE AGED; PREDNISONE; SEVERITY OF ILLNESS INDEX;

EID: 84945446278     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12602     Document Type: Article

References (10)

1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et-al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 2014; 43: 343-373.
2. Catley MC, Coote J, Bari M, Tomlinson KL,. Monoclonal antibodies for the treatment of asthma. Pharmacol. Ther. 2011; 132: 333-351.
3. Prazma CM, Wenzel S, Barnes N, Douglass JA, Hartley BF, Ortega H,. Characterisation of an OCS-dependent severe asthma population treated with mepolizumab. Thorax 2014; 69: 1141-1142.
4. Hyland ME, Whalley B, Jones RC, Masoli M,. A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales. Qual. Life Res. 2015; 24: 631-639.
5. Wenzel SE,. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 2012; 18: 716-725.
6. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID,. Asthma exacerbations and sputum eosinophil counts: a randomised control trial. Lancet 2002; 360: 1715-1721.
7. Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, Lomas DA, Barer MR, Johnston SL, Pavord ID, et-al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2012; 186: 48-55.
8. Bafadhel M, Davies L, Calverley PM, Aaron SD, Brightling CE, Pavord ID,. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur. Respir. J. 2014; 44: 789-791.
9. McDonald VM, Vertigan AE, Gibson PG,. How to set up a severe asthma service. Respirology 2011; 16: 900-911.
10. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR,. Development and validation of a questionnaire to measure asthma control. Eur. Respir. J. 1999; 14: 902-907.